The presented study demonstrates that CPT-11, an important and current clinical drug, could activate the ERK1/2 and Akt signaling and AP-1transcription factor to upregulate the MSH2 expression and hence consequently decrease the cytotoxicity of CPT-11 to CRC cells. Here, MAPK3 is linked to colorectal carcinoma.